Q1 2025 Results

Bristol-Myers Squibb’s first-quarter 2025 results demonstrate a strategic transition toward its growth portfolio, which achieved a 16% year-over-year increase in net sales. While total global net sales reached $11.2 billion, representing a 6% decline compared to the previous year, the company’s performance was bolstered by strong demand for key assets such as Opdivo, Breyanzi, and Camzyos. The company continues to navigate the impact of generic competition on legacy products, including Revlimid, Sprycel, and Pomalyst, while simultaneously advancing a robust pipeline of clinical and regulatory milestones.

Financial execution remains disciplined, with the company raising its full-year 2025 guidance for both total revenues and non-GAAP earnings per share. The updated revenue outlook of $45.8 billion to $46.8 billion reflects favorable foreign exchange impacts and stronger-than-anticipated performance in the legacy portfolio. Non-GAAP diluted earnings per share are now projected in the range of $6.70 to $7.00. The company maintains a focus on capital allocation, prioritizing debt reduction—having achieved approximately $6 billion in paydowns toward a $10 billion target—while sustaining its commitment to shareholder dividends and share repurchases.

Operational highlights for the quarter include the successful U.S. launch of Opdivo Qvantig and continued volume growth for established oncology and immunology treatments. The company is entering a data-rich period through 2027, with multiple pivotal data readouts expected for new molecular entities and life-cycle management programs. By leveraging improved market access and maintaining a strong balance sheet, the organization aims to sustain its long-term growth trajectory despite ongoing macroeconomic and regulatory challenges.